Few leaders in biotechnology have successfully willed an entirely new class of medicine into existence, but Oak’s newest advisor, John Maraganore, did exactly that. As the founding CEO of Alnylam Pharmaceuticals, he spent nearly two decades translating the raw biological discovery of RNA interference from a risky lab concept into a multi-billion-dollar global commercial reality. Along the way, he pioneered a corporate blueprint for the modern biotech era.

https://www.oakhcft.com/blog-post/welcoming-john-maraganore-a-conversation-on-ai-drug-discovery-and-believing-before-the-market-does